Since anti-PD-L1 partially overcomes inhibitory effects of OCs on T-cell activation and proliferation, these results suggest potential therapeutic benefit of combining CD38 and PD-1/PD-L1 mAbs to block OC-induced immunosuppression in MM. This evidence concerns the gene CD274 and Miyoshi myopathy.